Recruiting
Phase 3

Dose-Intensified RT

Sponsor:

Mayo Clinic

Code:

NCT07935889

Conditions

Glioblastoma, IDH-Wildtype

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

F-18 Fluoroethyltyrosine

Fluorodopa F 18

Magnetic Resonance Imaging

Study Details

Brief summary:

This clinical trial studies how well advanced imaging-guided standard dose versus (vs.) dose-intensified radiation therapy (RT) and dose-intensified accelerated RT works in treating patients with newly diagnosed glioblastoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. During dose-intensified RT, a higher dose than normal of radiation therapy is delivered over 6 weeks. During dose-intensified accelerated RT, the higher dose of radiation therapy is delivered over a shorter amount of time (2 weeks) than normal (6 weeks). Patients also undergo an advanced brain imaging positron emission tomography (PET)/computed tomography (CT) scan (using a radioactive drug called either FET or FDOPA) prior to RT to that may help doctors better plan the treatment. Dose-intensified and dose-intensified accelerated radiation therapy may be effective in treating patients with newly diagnosed glioblastoma. Giving dose-intensified RT or dose-intensified accelerated RT guided by advanced imaging may work better than standard dose RT in treating patients with newly diagnosed glioblastoma.

IND Numbers: 61300, 140882, 176402, 154793, 167879

Conditions

Glioblastoma, IDH-Wildtype

Study ID

NCT07935889

Start date

Nov 13, 2026

Status verified date

Nov, 2026

Completion date

Nov 30, 2035

Anticipated

Primary completion date

Nov 30, 2035

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age ≥ 18 years
  • Histological confirmation of glioblastoma (IDH-wildtype)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 3 at baseline
  • Provide written informed consent or have a Legally Authorized Representative (LAR) who is responsible for the care and well-being of the potential study participant, provide consent in accordance with ethical, regulatory, and institutional requirements
  • Willing to return to enrolling institution for follow-up either in-person or by video visit (where indicated)

Exclusion Criteria:

  • Known to be pregnant or nursing
  • Unable to undergo MRI scans with contrast (such as patients with devices or metal in head that is MRI incompatible)
  • Unable to undergo amino acid PET (FET or FDOPA) scan (such as allergy to the contrast/tracer, or technical or patient factors per the discretion of the treating physician)
  • Prior radiation (including tile-based brachytherapy) or chemotherapy for glioblastoma (note: prior cancer diagnoses and treatment for other cancers are not exclusion criteria, and multiple surgeries prior to enrollment is not an exclusion criteria)

Study Design

Enrollment

292 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Arm A (dose-intensified radiation therapy)

Patients undergo thirty treatment fractions of dose-intensified proton or photon radiation therapy QD (Monday-Friday) over 6 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive SOC temozolomide during and/or after radiation therapy at the discretion of the treating team. Additionally, patients receive FET via injection or FDOPA IV and undergo PET/CT prior to treatment and optionally during treatment and follow-up. Patients also undergo MRI and blood sample collection throughout the study.

active comparator: Arm B (standard radiation therapy)

Patients undergo thirty treatment fractions of standard proton or photon radiation therapy QD (Monday-Friday) over 6 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive SOC temozolomide during and/or after radiation therapy at the discretion of the treating team. Additionally, patients receive FET via injection or FDOPA IV and undergo PET/CT prior to treatment and optionally during treatment and follow-up. Patients also undergo MRI and blood sample collection throughout the study.

experimental: Arm C (dose-intensified accelerated radiation therapy)

Patients undergo ten treatment fractions of dose-intensified accelerated proton or photon radiation therapy QD (Monday-Friday) over 2 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive SOC temozolomide during and/or after radiation therapy at the discretion of the treating team. Additionally, patients receive FET via injection or FDOPA IV and undergo PET/CT prior to treatment and optionally during treatment and follow-up. Patients also undergo MRI throughout the study.

active comparator: Arm D (accelerated radiation therapy)

Patients undergo ten treatment fractions of accelerated proton or photon radiation therapy QD (Monday-Friday) over 2 weeks in the absence of unacceptable toxicity. Patients may also receive SOC temozolomide during and/or after radiation therapy at the discretion of the treating team. Additionally, patients receive FET via injection or FDOPA IV and undergo PET/CT prior to treatment and optionally during treatment and follow-up. Patients also undergo MRI throughout the study.

Interventions

Biospecimen Collection

Undergo blood sample collection

Computed Tomography

Undergo FET or FDOPA PET/CT

F-18 Fluoroethyltyrosine

Given via injection

Fluorodopa F 18

Given IV

Magnetic Resonance Imaging

Undergo MRI

Dose-intensified Photon Beam Radiation Therapy

Undergo dose-intensified photon radiation therapy

Standard Photon Beam Radiation Therapy

Undergo standard photon radiation therapy

Dose-intensified Accelerated Photon Beam Radiation Therapy

Undergo dose-intensified accelerated photon radiation therapy

Accelerated Photon Beam Radiation Therapy

Undergo accelerated photon radiation therapy

Positron Emission Tomography

Undergo FET or FDOPA PET/CT

Proton Beam Radiation Therapy

Undergo dose-intensified proton radiation therapy

Proton Beam Radiation Therapy

Undergo standard proton radiation therapy

Proton Beam Radiation Therapy

Undergo dose-intensified accelerated proton radiation therapy

Proton Beam Radiation Therapy

Undergo accelerated proton radiation therapy

Questionnaire Administration

Ancillary studies

Temozolomide

Given SOC temozolomide

Primary outcome measure

  • Overall survival (Cohort 1) [ Time Frame: Up to 18 months ]
  • Overall survival (Cohort 2) [ Time Frame: Up to 12 months ]

Central Contacts and Locations

Central contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Locations

Mayo Clinic Health System in Albert Lea

Recruiting

Albert Lea, Minnesota, United States, 56007

Contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Principal Investigator:

John E. Yeakel, MD

Mayo Clinic Health Systems-Mankato

Recruiting

Mankato, Minnesota, United States, 56001

Contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Principal Investigator:

Jason T. Hayes, MD

Mayo Clinic Radiation Therapy - Northfield

Recruiting

Northfield, Minnesota, United States, 55057

Contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Principal Investigator:

James L. Leenstra, MD

Mayo Clinic in Rochester

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Principal Investigator:

William Breen, MD

Mayo Clinic Health System-Eau Claire Clinic

Recruiting

Eau Claire, Wisconsin, United States, 54701

Contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Principal Investigator:

Now Bahar Alam, MD

Mayo Clinic Health System-Franciscan Healthcare

Recruiting

La Crosse, Wisconsin, United States, 54601

Contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Principal Investigator:

Abigail L. Stockham, MD

More Information

Sponsor

Mayo Clinic

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.